The Choice Between Belimumab And Anifrolumab: Analysis Of A Monocentric Cohort

This study analyzed the factors influencing the choice between belimumab (BEL) and anifrolumab (ANI) in treating Systemic Lupus Erythematosus (SLE) in a cohort of 61 patients. ANI was more frequently chosen for patients with a chronic-active disease course and active cutaneous manifestations, including subacute lupus and alopecia with lupus hair. In contrast, BEL was preferred for those with a relapsing-remitting disease course and active arthritis, particularly non-deforming and non-erosive arthritis. The study highlights that the clinical phenotype primarily guides the choice of biologic drug, aligning with evidence from registration trials, and suggests that future real-life studies and predictive biomarkers could enhance personalized therapy in precision medicine.